Literature DB >> 33387188

Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample.

Kirk E Evoy1,2,3, Jordan R Covvey4, Alyssa M Peckham5,6, Kelly R Reveles7,8.   

Abstract

Background Reports of gabapentinoid (gabapentin and pregabalin) misuse are on the rise, but few studies have assessed this within the general US population. Objective Describe lifetime misuse/abuse/non-prescribed obtainment of gabapentinoids and descriptive characteristics associated with such actions in a US general population sample. Setting This cross-sectional questionnaire was administered online by Qualtrics® research panel aggregator via quota-based sampling. Methods Data were collected from a sample of respondents that mirrored the general US population aged 18-59 years with regards to age, geographic region, ethnicity, income, and education level, based on most recent census data. Misuse/abuse/non-prescribed obtainment was collectively defined as use of a gabapentinoid for reasons other than a diagnosed medical condition, using with the intention of altering one's state of consciousness, or obtaining without a prescription. A multivariable logistic regression model was created to predict misuse/abuse/non-prescribed obtainment of gabapentinoids, incorporating relevant covariates. Main outcome measure Proportion of sample indicating lifetime misuse/abuse/non-prescribed obtainment of gabapentinoids. Results Among 1,843 respondents, 121 (6.6%) reported gabapentinoid misuse/abuse/non-prescribed obtainment. Specifically, 2.1% (n = 39) and 1.5% (n = 27) of respondents for gabapentin and pregabalin, respectively, met study criteria for abuse. Opioids were the most common medication co-administered with gabapentinoids (among 50-70% of respondents) for misuse/abuse. Previous treatment for addiction (OR: 2.61, 95% CI: 1.32-5.14, p = 0.005) and the total attitudinal risk score (OR: 1.14, 95% CI: 1.09-1.19, p < 0.001) were associated with gabapentinoid misuse/abuse/non-prescribed obtainment. Conclusion Among those surveyed, 6.6% reported previous gabapentinoid misuse/abuse/non-prescribed obtainment, providing one of the first estimates within a nationally distributed, US general population sample.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature.

Entities:  

Keywords:  Abuse; Diversion; Gabapentin; Gabapentinoid; Misuse; Pregabalin

Year:  2021        PMID: 33387188     DOI: 10.1007/s11096-020-01217-8

Source DB:  PubMed          Journal:  Int J Clin Pharm


  4 in total

1.  Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS).

Authors:  Kirk E Evoy; Jordan R Covvey; Alyssa M Peckham; Leslie Ochs; Kyle E Hultgren
Journal:  Res Social Adm Pharm       Date:  2018-06-28

2.  Pregabalin Abuse amongst Opioid Substitution Treatment Patients.

Authors:  S McNamara; S Stokes; R Kilduff; A Shine
Journal:  Ir Med J       Date:  2015 Nov-Dec

3.  Parental history of substance use disorders (SUD) and SUD in offspring: a controlled family study of bipolar disorder.

Authors:  Timothy E Wilens; Amy Yule; MaryKate Martelon; Courtney Zulauf; Stephen V Faraone
Journal:  Am J Addict       Date:  2014-03-15

4.  Financial Hardship from Purchasing Medications for Senior Citizens Before and After the Medicare Modernization Act of 2003 and the Patient Protection and Affordable Care Act of 2010: Findings from 1998, 2001, and 2015.

Authors:  Anthony W Olson; Jon C Schommer; David A Mott; Lawrence M Brown
Journal:  J Manag Care Spec Pharm       Date:  2016-10
  4 in total
  2 in total

1.  Authors' Reply to Bonnet et al. "Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update".

Authors:  Kirk E Evoy; Sarvnaz Sadrameli; Jillian Contreras; Jordan R Covvey; Alyssa M Peckham
Journal:  Drugs       Date:  2021-03-18       Impact factor: 9.546

2.  Toxicological Relevance of Pregabalin in Heroin Users: A Two-Year Postmortem Population Study.

Authors:  Limon K Nahar; Kevin Murphy; Sue Paterson
Journal:  J Anal Toxicol       Date:  2022-05-20       Impact factor: 3.220

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.